(Q35901886)

11 August 2017

1 reference

title

Treatment-resistant panic disorder. (English)

1 reference

11 August 2017

Borwin Bandelow

1

1 reference

PubMed ID

15448584

11 August 2017

Eckart Rüther

series ordinal

2

1 reference

11 August 2017

1 October 2004

1 reference

11 August 2017

1 reference

11 August 2017

9

1 reference

11 August 2017

725-739

1 reference

11 August 2017

10

1 reference

Efficacy of open-label nefazodone treatment in patients with panic disorder.

11 August 2017

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022379

Double-blind, placebo-controlled, crossover trial of inositol treatment for panic disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022379

Diazepam and Propranolol in Panic Disorder and Agoraphobia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022379

Benzodiazepine dependency discontinuation: focus on the chemical dependency detoxification setting and benzodiazepine-polydrug abuse

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022379

Long-term Therapeutic Use of Benzodiazepines

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022379

Long-term Therapeutic Use of Benzodiazepines

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022379

Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. I. Efficacy in short-term treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022379

Clomipramine for panic disorder: I. The first 10 weeks of a long-term comparison with imipramine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022379

Response of panic disorder to fixed doses of alprazolam or imipramine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022379

Treatment of Agoraphobia With Group Exposure In Vivo and Imipramine

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022379

Sertraline in the treatment of panic disorder: a double-blind multicenter trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022379

Sertraline in the treatment of panic disorder: a flexible-dose multicenter trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022379

Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022379

Double-blind pilot trial of desipramine versus fluoxetine in panic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022379

Efficacy of usual antidepressant dosing regimens of fluoxetine in panic disorder: randomised, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022379

Serotonin function in panic disorder: a double blind placebo controlled study with fluvoxamine and ritanserin

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022379

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Posttraumatic Stress Disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022379

Early improvement predicts endpoint remission status in sertraline and placebo treatments of panic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022379

Personality disorder and social anxiety predict delayed response in drug and behavioral treatment of panic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022379

Predictors and outcome in panic disorder: a 2-year prospective follow-up study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022379

Predicting who benefits from psychoeducation and self help for panic attacks

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022379

A dose-finding and discontinuation study of clomipramine in panic disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022379

The prediction of nonresponse to pharmacotherapy in panic disorder: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022379

Reboxetine, a selective norepinephrine reuptake inhibitor, is an effective and well-tolerated treatment for panic disorder

21 January 2018

2 references

https://api.crossref.org/works/10.1017%2FS1092852900022379

21 January 2018

https://api.crossref.org/works/10.1017%2FS1092852900022379

7 January 2021

Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder: twenty-four-week placebo-controlled dose-ranging study

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022379

Group cognitive-behavioral treatment of panic disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022379

Psychological treatment of panic: work in progress on outcome, active ingredients, and follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022379

Combined paroxetine and clonazepam treatment strategies compared to paroxetine monotherapy for panic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022379

Usefulness of olanzapine in refractory panic attacks.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022379

Pindolol augmentation in patients with treatment-resistant panic disorder: A double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022379

Multicenter collaborative panic disorder severity scale

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022379

Review of the long-term effectiveness of cognitive behavioral therapy compared to medications in panic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022379

Does brief dynamic psychotherapy reduce the relapse rate of panic disorder?

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022379

Pharmacological treatment of agoraphobia: imipramine versus imipramine with programmed practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022379

Context in the clinic: how well do cognitive-behavioral therapies and medications work in combination?

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022379

Comparison of aerobic exercise, clomipramine, and placebo in the treatment of panic disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022379

EMDR for panic disorder with agoraphobia: comparison with waiting list and credible attention-placebo control conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022379

[Conflict-centered individual therapy or integration of psychotherapy methods. Process of change in client-centered psychotherapy with and without behavioral exposure therapy in agoraphobia with panic disorder]

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022379

Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: A randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022379

Behavioral treatment of panic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022379

Protective effects of imipramine maintenance treatment in panic disorder with agoraphobia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022379

Sertraline treatment of panic disorder: results of a long-term study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022379

Interactive model of therapeutic response in panic disorder: moclobemide, a case in point

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022379

Alprazolam and exposure alone and combined in panic disorder with agoraphobia. A controlled study in London and Toronto

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022379

Valproate treatment of panic disorder and lactate-induced panic attacks.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022379

Randomised placebo-controlled trial of moclobemide, cognitive-behavioural therapy and their combination in panic disorder with agoraphobia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022379

Valproic acid and panic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022379

The efficacy and safety of moclobemide compared to clomipramine in the treatment of panic disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022379

Moclobemide and fluoxetine for panic disorder. International Panic Disorder Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022379

Treatment of endogenous anxiety with phobic, hysterical, and hypochondriacal symptoms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022379

Early coadministration of clonazepam with sertraline for panic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022379

Psychological strategies for discontinuing benzodiazepine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022379

Clinical Experience with Mirtazapine in the Treatment of Panic Disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022379

A Comparison of Fluvoxamine, Cognitive Therapy, and Placebo in the Treatment of Panic Disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022379

Treating Medication-Resistant Panic Disorder: Predictors and Outcome of Cognitive-Behavior Therapy in a Brazilian Public Hospital

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022379

The Use of the Panic and Agoraphobia Scale (P & A) in a controlled clinical trial1

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022379

Cognitive-behavioral therapy for panic disorder: a review of treatment elements, strategies, and outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022379

7 January 2021

The relative efficacy of high-dose buspirone and alprazolam in the treatment of panic disorder: a double-blind placebo-controlled study

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022379

7 January 2021

Clinical experiments in maintenance and discontinuation of imipramine therapy in panic disorder with agoraphobia

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022379

7 January 2021

WCA recommendations for the long-term treatment of panic disorder.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022379

7 January 2021

Benzodiazepines in the Treatment of Anxiety

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022379

7 January 2021

The effect of personality on withdrawal severity and taper outcome in benzodiazepine dependent patients

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022379

7 January 2021

Sertraline versus paroxetine in the treatment of panic disorder: an acute, double-blind noninferiority comparison.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022379

7 January 2021

A controlled study of cognitive behaviour therapy with buspirone or placebo in panic disorder with agoraphobia

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022379

7 January 2021

Two-year follow-up of agoraphobics after exposure and imipramine

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022379

7 January 2021

Lorazepam vs. alprazolam in the treatment of panic disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022379

7 January 2021

Clonazepam in the treatment of panic disorder with or without agoraphobia: a dose-response study of efficacy, safety, and discontinuance. Clonazepam Panic Disorder Dose-Response Study Group

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022379

7 January 2021

Sertraline versus imipramine treatment of comorbid panic disorder and major depressive disorder.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022379

7 January 2021

A controlled, prospective, 1-year trial of citalopram in the treatment of panic disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022379

7 January 2021

Cardiovascular and symptomatic reduction effects of alprazolam and imipramine in patients with panic disorder: results of a double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022379

7 January 2021

Drug treatment of panic disorder. Comparative efficacy of alprazolam, imipramine, and placebo. Cross-National Collaborative Panic Study, Second Phase Investigators

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022379

7 January 2021

Serotonin uptake inhibitors are superior to imipramine and alprazolam in alleviating panic attacks: a meta-analysis

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022379

7 January 2021

DELINEATION OF TWO DRUG-RESPONSIVE ANXIETY SYNDROMES

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022379

7 January 2021

Long-term evaluation of paroxetine, clomipramine and placebo in panic disorder. Collaborative Paroxetine Panic Study Investigators

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022379

7 January 2021

Outcome assessment and clinical improvement in panic disorder: evidence from a randomized controlled trial of fluoxetine and placebo. The Fluoxetine Panic Disorder Study Group

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022379

7 January 2021

The effect of citalopram in panic disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022379

7 January 2021

Escitalopram in the treatment of panic disorder: a randomized, double-blind, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022379

7 January 2021

Imipramine and Brief Therapist-Aided Exposure in Agoraphobics Having Self-exposure Homework

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022379

7 January 2021

Paroxetine in the treatment of panic disorder. A randomised, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022379

7 January 2021

Paroxetine, Clomipramine, and Cognitive Therapy in the Treatment of Panic Disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022379

7 January 2021

International study of expert judgment on therapeutic use of benzodiazepines and other psychotherapeutic medications: VI. Trends in recommendations for the pharmacotherapy of anxiety disorders, 1992-1997.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022379

7 January 2021

Treatment of phobias. I. Comparison of imipramine hydrochloride and placebo

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022379

7 January 2021

A comparison of the post-marketing safety of four selective serotonin re-uptake inhibitors including the investigation of symptoms occurring on withdrawal

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022379

7 January 2021

Treatment of panic disorder with agoraphobia: comparison of fluvoxamine, placebo, and psychological panic management combined with exposure and of exposure in vivo alone

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022379

7 January 2021

Clomipramine treatment of agoraphobic women. An eight-week controlled trial

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022379

7 January 2021

Unemployment and Emergency Room Visits Predict Poor Treatment Outcome in Primary Care Panic Disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022379

7 January 2021

Continuing treatment of panic disorder after acute response: randomised, placebo-controlled trial with fluoxetine. The Fluoxetine Panic Disorder Study Group

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022379

7 January 2021

Discontinuation of benzodiazepine treatment: efficacy of cognitive- behavioral therapy for patients with panic disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022379

7 January 2021

Sertraline in the treatment of panic disorder. A multi-site, double-blind, placebo-controlled, fixed-dose investigation

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022379

7 January 2021

Buspirone in the treatment of panic disorder: a controlled pilot comparison with clorazepate.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022379

7 January 2021

Cognitive and performance-based treatments for panic attacks in people with varying degrees of agoraphobic disability

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022379

7 January 2021

A crossover study of focused cognitive therapy for panic disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022379

7 January 2021

Cognitive behavioral treatment compared with nonprescriptive treatment of panic disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022379

7 January 2021

Combined pharmacological and behavioral treatment for agoraphobia

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022379

7 January 2021

A comparison of cognitive therapy, applied relaxation and imipramine in the treatment of panic disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022379

7 January 2021

Predictors of 1-year outcome for patients with panic disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022379

7 January 2021

Olanzapine and panic attacks

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022379

7 January 2021

Two-year follow-up of exposure and imipramine treatment of agoraphobia

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022379

7 January 2021

Long-term therapeutic use of benzodiazepines. I. Effects of abrupt discontinuation

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022379

7 January 2021

[Rapid response of a disorder to the addition of lithium carbonate: panic resistant to tricyclic antidepressants]

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022379

7 January 2021

A randomized, double-blind, placebo-controlled study of the effects of adjunctive paroxetine in panic disorder patients unsuccessfully treated with cognitive-behavioral therapy alone.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022379

7 January 2021

Treatment of negative crises (panic attacks)

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022379

7 January 2021

Efficacy of telephone-administered behavioral therapy for panic disorder with agoraphobia

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022379

7 January 2021

A comparison of paroxetine, clomipramine and placebo in the treatment of panic disorder. Collaborative Paroxetine Panic Study Investigators

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022379

7 January 2021

Withdrawal reactions with selective serotonin re-uptake inhibitors as reported to the WHO system

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022379

7 January 2021

A comparison of alprazolam and behavior therapy in treatment of panic disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022379

7 January 2021

The effects of treatment compliance on outcome in cognitive-behavioral therapy for panic disorder: quality versus quantity.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022379

7 January 2021

A comparison of bibliotherapy and group therapy in the treatment of panic disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022379

7 January 2021

Eye movement desensitization and reprocessing treatment for panic disorder: a controlled outcome and partial dismantling study.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022379

7 January 2021

Impact of cognitive-behavioral treatment on quality of life in panic disorder patients.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022379

7 January 2021

10.1017/S1092852900022379

Identifiers

DOI

1 reference

11 August 2017

1 reference

PubMed ID

15448584